Kalshi and Polymarket bets on clinical trials criticized as ‘ghastly’0

• Beauty / Wellness, Biotech & Health, CoECI News, Energy & Environment Newsletter, Gaming News Roundup, Gear / Gear News and Events, Global, Global Precipitation, global warming, globalstar, HEALTH, Health Care, health-freelancer, HealthTech, healthtech startups, Home, House, Human Health and Performance, News, newsletter, Newsletters, Nexstar Media Wire News, People News, Photovogue / Editorial / News, Politics / Politics News, Property / News, Reviews, reviews-rit-ads, Science / Health, Security / Security News, shop, Shop Beauty, Shopping, starlink, Surface Water, trending-uk, WORLD, World / Middle East, World Health Organization
• August 7, 2026

Kalshi and Polymarket say allowing people to bet on the outcomes of clinical trials and FDA drug approvals provides valuable information about drug development. But researchers warn the bets could incentivize insider trading and interfere with the integrity of the process. Fred Tanneau/AFP via Getty Images hide caption toggle caption Fred Tanneau/AFP via Getty Images